Dr. Lei Jiang, PhD
Position:
· Professor / Director, Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City, Zhejiang Province, 325000, China
Institution:
· The First Affiliated Hospital of Wenzhou Medical University
Education:
· 2004 - 2009: Ph.D. (Cell Biology), Zhejiang University, Hangzhou, China
· 1997 - 2001: B.Sc. (Biology), Zhejiang University, Hangzhou, China
Work Experience:
· 2021 - Present: Professor / Director, Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
· 2018 - 2020: Professor / Deputy Director, Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
· 2012 - 2017: Associate Professor / Deputy Director, Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
· 2018 - 2019: Visiting Scientist, Medical University of South Carolina
· 2013 - 2014: Visiting Scholar, University of North Texas Health Science Center, USA
· 2009 - 2011: Assistant Professor, Central Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
· 2006 - 2008: Research Assistant, Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong (CUHK), Hong Kong
· 2001 - 2004: Research Assistant, Institute of Medical Sciences, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Research Interests:
· Cancer Biology
Honors and Awards:
· High-level talents of health innovation in Zhejiang province (2021)
· 551 talent program in Wenzhou City of Zhejiang province (2016)
· Top talent young people in Wenzhou (2016)
Journal Editorial Boards:
· Editor, World Journal of Clinical Oncology (2018 - Present)
Research Grants:
1. National Natural Science Foundation of China (Grant No. 82272652)
o Mechanisms of Trx-1 regulating glucose metabolism reprogramming in ferroptosis resistance of colorectal cancer cells under metabolic stress
o Period: 2023 - 2026
o 520,000 RMB
o Principal Investigator
2. Zhejiang Provincial Natural Science Foundation of China (Grant No. LY19H160024)
o The role and molecular mechanisms of Trx-1 in regulation of colorectal cancer cell glucose metabolism under metabolic stress
o Period: 2019 - 2021
o 100,000 RMB
o Principal Investigator
3. Wenzhou Science-technology Program (Y20180081)
o Anti-tumor effect and molecular mechanism of targeting Trx-1 combined with glucose metabolism inhibitors on colorectal cancer
o Period: 2019 - 2021
o 30,000 RMB
o Principal Investigator
4. National Natural Science Foundation of China (Grant No. 81672385)
o The function and molecular mechanisms of Trx-1 nuclear translocation during IL-6 induced epithelial-mesenchymal transition and invasion and metastasis of colorectal cancer
o Period: 2017 - 2020
o 570,000 RMB
o Principal Investigator
5. Zhejiang Provincial Natural Science Foundation of China (Grant No. LY15H160057)
o Molecular mechanisms of Trx-1-induced colorectal cancer invasion and metastasis through epithelial-mesenchymal transition
o Period: 2015 - 2017
o 100,000 RMB
o Principal Investigator
6. Medicine and Health Technology Program of Zhejiang Province (2013KYA129)
o Thioredoxin-1 inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) inhibits growth, migration and invasion of colorectal cancer cells and mechanism study
o Period: 2013 - 2016
o 30,000 RMB
o Principal Investigator
7. National Natural Science Foundation of China (Grant No. 81101823)
o The study of thioredoxin 1 function on the downstream signal cascade of S100P leading to colon cancer growth and metastasis
o Period: 2012 - 2014
o 220,000 RMB
o Principal Investigator
8. Zhejiang Provincial Natural Science Foundation of China (Grant No. Y2100018)
o Targeting S100P inhibits colon cancer growth and metastasis by lentivirus-mediated RNA interference and mechanism study
o Period: 2010 - 2013
o 100,000 RMB
o Principal Investigator
9. Wenzhou Science-technology Program (Y20100062)
o Lentiviral vector expressing TIEG1 gene inhibits pancreatic cancer growth and enhances chemosensitivity
o Period: 2010 - 2013
o 50,000 RMB
o Principal Investigator
10. Scientific Research Fund of Zhejiang Provincial Education Department (Y200906317)
o Lentiviral vector expressing TIEG1 gene with breast cancer specific promoter for targeting breast cancer
o Period: 2009 - 2012
o 12,000 RMB
o Principal Investigator
Patent:
· DNA aptamer specifically binding S100P protein, its screening, identification and application. Invention patent CN109837281B, Inventors: Jiang Lei, Sun Wenjing, Ni Wuhua
Publications (First Author/*Corresponding Author):
1. Liu Y, Yang M, Fan L, He Y, Dai E, Liu M, Jiang L*,Yang Z*, Li S*. Frameshift variants in the C-terminal of CTNNB1 cause familial exudative vitreoretinopathy by AXIN1-mediated ubiquitin-proteasome degradation condensation. Int J Biol Macromol. 2023 Dec 12:128570. doi: 10.1016/j.ijbiomac.2023.128570. Epub ahead of print. PMID: 38096938.
2. Tang T, Fang D, Ji Z, Zhong Z, Zhou B, Ye L, Jiang L*, Sun X*. Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells. Cell Oncol (Dordr). 2024 Apr;47(2):607-621 doi: 10.1007/s13402-023-00887-6.
3. Wu A, Fang D, Liu Y, Shi X, Zhong Z, Zhou B, Ye L, Sun X, Jiang L*. Nuclear translocation of thioredoxin-1 promotes colorectal cancer development via modulation of the IL-6/STAT3 signaling axis through interaction with STAT3. Theranostics 2023; 13(14):4730-4744. doi:10.7150/thno.85460.
4. Lu F, Fang D, Li S, Zhong Z, Jiang X, Qi Q, Liu Y, Zhang W, Xu X, Liu Y, Zhu W, Jiang L*. Thioredoxin 1 supports colorectal cancer cell survival and promotes migration and invasion under glucose deprivation through interaction with G6PD. Int J Biol Sci 2022; 18(14):5539-5553. doi:10.7150/ijbs.71809.
5. Chen H, Qi Q, Wu N, Wang Y, Feng Q, Jin R, Jiang L*. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer. Redox Biol. 2022 Aug 4;55:102426. doi: 10.1016/j.redox.2022.102426.
6. Qiongying Zhang, Ruichun Bi, Xiaodong Bao, Xiaohui Xu, Daoquan Fang, Lei Jiang∗. MYT1L promotes the migration and invasion of glioma cells through activation of Notch signaling pathway.ScienceAsia.2022,48 doi: 10.2306/scienceasia1513-1874.2022.100
7. Xu F, Chen M, Chen H, Wu N, Qi Q, Jiang X, Fang D, Feng Q, Jin R, Jiang L*. The Curcumin Analog Da0324 Inhibits the Proliferation of Gastric Cancer Cells via HOTAIRM1/miR-29b-1-5p/PHLPP1 Axis. J Cancer 2022; 13(8):2644-2655. doi:10.7150/jca.69970.
8. Zhu W#, Jiang L#, Li Y, Sun J, Lin C, Huang X, Ni W. DNA comethylation analysis reveals a functional association between BRCA1 and sperm DNA fragmentation. Fertil Steril. 2022 Mar 4:S0015-0282(22)00060-7. doi: 10.1016/j.fertnstert.2022.01.025.
9. Liu F, Shi Z, Bao W, Zheng J, Chen K, Lin Z, Song HN, Luo X, Dong Q, Jiang L, Wang Y, Chen G, Chen X. ZIC2 promotes colorectal cancer growth and metastasis through the TGF-β signaling pathway. Exp Cell Res. 2022 Jun 15;415(2):113118. doi: 10.1016/j.yexcr.2022.113118.
10. He L, Chen H, Qi Q, Wu N, Wang Y, Chen M, Feng Q, Dong B, Jin R*, Jiang L*. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo. Eur J Pharmacol. 2022 Apr 5;920:174823.
11. Qin Z, Yuan X, Liu J, Shi Z, Cao L, Yang L, Wu K, Lou Y, Tong H, Jiang L*, Du J*. Albuca Bracteata Polysaccharides Attenuate AOM/DSS Induced Colon Tumorigenesis via Regulating Oxidative Stress, Inflammation and Gut Microbiota in Mice. Front Pharmacol. 2022 Feb 21;13:833077.
12. Feng Q, Tang LJ, Luo DH, Wang Y, Wu N, Chen H, Chen MX, Jiang L*, Jin R*. Metabolic Syndrome-Related Hyperuricemia is Associated with a Poorer Prognosis in Patients with Colorectal Cancer: A Multicenter Retrospective Study. Cancer Manag Res. 2021 Nov 24;13:8809-8819. doi: 10.2147/CMAR.S338783.
13. Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X, Jiang L*, Ye L*. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021 Nov 13;12(11):1079. doi: 10.1038/s41419-021-04367-3.
14. Zhang W, Fang D, Li S, Bao X, Jiang L*, Sun X*. Construction and Validation of a Novel Ferroptosis-Related lncRNA Signature to Predict Prognosis in Colorectal Cancer Patients. Front Genet. 2021 Oct 28;12:709329.doi: 10.3389/fgene.2021.709329
15. Ji Z, Tang T, Chen M, Dong B, Sun W, Wu N, Chen H, Feng Q, Yang X, Jin R*, Jiang L*. C-Myc-activated long non-coding RNA LINC01050 promotes gastric cancer growth and metastasis by sponging miR-7161-3p to regulate SPZ1 expression. J Exp Clin Cancer Res. 2021 Nov 8;40(1):351. doi: 10.1186/s13046-021-02155-7.
16. Yuan X, Xue J, Tan Y, Yang Q, Qin Z, Bao X, Li S, Pan L, Jiang Z, Wang Y, Lou Y*, Jiang L*, Du J*. Albuca Bracteate Polysaccharides Synergistically Enhance the Anti-Tumor Efficacy of 5-Fluorouracil Against Colorectal Cancer by Modulating β-Catenin Signaling and Intestinal Flora. Front Pharmacol. 2021 Sep 3;12:736627. doi: 10.3389/fphar.2021.736627.
17. Sun X#; Lin F#; Sun W#; Zhu W, Fang D, Luo L, Li S, Zhang W, Jiang, L*; Exosome-transmitted miRNA-335-5p promotes colorectal cancer invasion and metastasis by facilitating epithelial-mesenchymal transition via targeting RASA1, Molecular Therapy: Nucleic Acid, 2021, 24:164-174.
18. Zhu W#, Jiang L#, Pan C, Sun J, Huang X, Ni W*. Deoxyribonucleic acid methylation signatures in sperm deoxyribonucleic acid fragmentation. Fertil Steril. 2021, 116 (5):1297-1307. doi: 10.1016/j.fertnstert.2021.06.025. (Co-first)
19. Luo L, Sun W, Zhu W, Li S, Zhang W, Xu X, Fang D, Grahn THM, Jiang L*, Zheng Y*. BCAT1 decreases the sensitivity of cancer cells to cisplatin by regulating mTOR-mediated autophagy via branched-chain amino acid metabolism. Cell Death Dis. 2021 Feb 10;12(2):169.
20. Sun W, Luo L, Fang D, Tang T, Ni W, Dai B, Sun H, Jiang L*. A Novel DNA Aptamer Targeting S100P Induces Antitumor Effects in Colorectal Cancer Cells. Nucleic Acid Ther. 2020 Dec;30(6):402-413.
Contact Information:
Phone: +86-13587873910, +86-577-55579127 (work)
E-mail: jiangleistone79@163.com; lei.jiang@wmu.edu.cn
